NEW SURVEY SHEDS LIGHT ON MOMS’ PERSPECTIVES ABOUT ADHD MEDICATIONS (Noven...
Moms of Children Taking ADHD Prescription Medication Feel Like They Are Doing the Right Thing, Yet Challenges and Knowledge Gaps Remain Miami, FL, New York, NY, October 17, 2012 -- A new online survey...
View ArticleU.S. FDA Approves New 60 mg Dosage Strength of Fluoxetine
, Oct. 11, 2011 /PRNewswire/ -- Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application...
View ArticleMenopause Drugs from Depomed, Hisamitsu Offer Benefits
Drugs developed for menopausal hot flashes by Depomed Inc. (DEPO) and Hisamitsu Pharmaceutical Co. (4530) are effective, according to staff reviewers at the Food and Drug Administration. While...
View ArticleU.S. FDA Approves Lower Dose Formulation of ANGELIQ® (Drospirenone and...
, Feb. 29, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ® (drospirenone...
View ArticleNoven Pharmaceuticals, Inc. press release : Noven acquires commercial rights...
NOVEN ACQUIRES COMMERCIAL RIGHTS TO MINIVELLE™ (ESTRADIOL TRANSDERMAL SYSTEM) Miami, FL and New York, NY, [December 3], 2012 - Noven Pharmaceuticals, Inc., a wholly- owned subsidiary of Hisamitsu...
View ArticleNOVEN ACQUIRES COMMERCIAL RIGHTS TO MINIVELLE™ (ESTRADIOL TRANSDERMAL...
Miami, FL and New York, NY, December 3, 2012 -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has acquired commercial rights to...
View ArticleF.D.A. Panel Advises Against Two Medicines to Treat Hot Flashes
Menopausal women looking for an approved alternative to hormones to treat hot flashes will probably not be getting immediate relief. Outside advisers to the Food and Drug Administration on Monday...
View ArticleMinivelle™ (Estradiol Transdermal System), The Smallest Estrogen Patch, Now...
Provides Effective Relief from Hot Flashes and Night Sweats Due to Menopause Google...
View ArticleMINIVELLE™ (ESTRADIOL TRANSDERMAL SYSTEM), THE SMALLEST ESTROGEN PATCH, NOW...
(Source: Noven Pharmaceuticals Inc) MINIVELLE™ (ESTRADIOL TRANSDERMAL SYSTEM), THE SMALLEST ESTROGEN PATCH, NOW AVAILABLE IN U.S. PHARMACIES Provides Effective Relief from Hot Flashes and Night Sweats...
View ArticleNoven Completes Phase 3 Clinical Program for Investigational Non-Hormonal...
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has completed the Phase 3 clinical...
View ArticleNOVEN SUBMITS NEW DRUG APPLICATION FOR INVESTIGATIONAL NON-HORMONAL THERAPY...
NOVEN SUBMITS NEW DRUG APPLICATION FOR INVESTIGATIONAL NON-HORMONAL THERAPY FOR MENOPAUSAL VASOMOTOR SYMPTOMS Miami, FL and New York, NY, August 29, 2012 -- Noven Pharmaceuticals, Inc., a wholly-owned...
View ArticleNoven Announces Phase 3 Results for Investigational Non-Hormonal Therapy for...
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced top-line results from the first of two planned...
View ArticleNOVEN ANNOUNCES FDA ADVISORY COMMITTEE VOTE ON INVESTIGATIONAL LOW-DOSE...
(Source: Noven Pharmaceuticals Inc) NOVEN ANNOUNCES FDA ADVISORY COMMITTEE VOTE ON INVESTIGATIONAL LOW-DOSE MESYLATE SALT OF PAROXETINE (LDMP) FOR VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE Miami,...
View ArticleNoven Announces FDA Advisory Committee Vote on Investigational Low-Dose...
Tweet MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory...
View ArticleNOVEN ANNOUNCES POSITIVE PHASE 3 DATA RESULTS FOR INVESTIGATIONAL LOW-DOSE...
Data from 12- and 24-Week Pivotal Studies Selected to Be Presented at The North American Menopause Society Annual Meeting , FL, NEW YORK, NY and , Oct. 3, 2012 /PRNewswire/ -- Noven Pharmaceuticals,...
View ArticleFDA Accepts Noven's NDA For An Investigational Nonhormonal Therapy For...
Google , FL and , Nov. 12, 2012 /PRNewswire/ -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that its New Drug Application (NDA) for...
View ArticleFDA ACCEPTS NOVEN’S NDA FOR AN INVESTIGATIONAL NONHORMONAL THERAPY FOR...
FDA ACCEPTS NOVEN'S NDA FOR AN INVESTIGATIONAL NONHORMONAL THERAPY FOR MENOPAUSAL VASOMOTOR SYMPTOMS Miami, FL, New York, NY, November 12, 2012 -- Noven Pharmaceuticals, Inc., a wholly-owned...
View ArticleNoven Pharmaceuticals, Inc. press release : FDA accepts Noven's NDA for an...
FDA ACCEPTS NOVEN'S NDA FOR AN INVESTIGATIONAL NONHORMONAL THERAPY FOR MENOPAUSAL VASOMOTOR SYMPTOMS Miami, FL and New York, NY, November 12, 2012 - Noven Pharmaceuticals, Inc., a wholly- owned...
View ArticleFDA advisers solidly against new menopause drugs
Medicine + Health Blog Health Resources Hospital / Urgent Care Locator Keywords Zipcode Category: Select Category: Hospitals Clinics Physicians and Surgeons Medical Equipment & Supplies All...
View Article